Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Post San Antonio Breast Cancer Symposium

Post San Antonio Breast Cancer Symposium editorial memo (2017) 10:50–51 DOI 10.1007/s12254-017-0334-4 Florian Fitzal Received: 9 May 2017 / Accepted: 9 May 2017 / Published online: 30 May 2017 © Springer-Verlag Wien 2017 The 2016 SABCS (San Antonio Breast Cancer Sympo- be a good surrogate marker to differentiate genomic sium) provided delegates with a number of interesting low from high risk. and some praxis-changing data. This issue of memo Finally, Greil and Gampenrieder [3] highlighted highlights the most relevant data from the SABCS pre- data regarding palliative systemic treatment. The PrE- sented by leading breast cancer experts from Austria. GOC 0102 trial investigated whether the combination Locoregional issues are addressed by Michael of fulvestrant plus everolimus is as safe and effective Hubalek [1]. He presents data regarding sentinel node as exemestane plus everolimus for patients with hor- biopsy after neoadjuvant therapy from the GANEA mone-receptor positive, HER2-negative disease. The trial in patients with clinical node-negative disease. pan-PI3K inhibitor buparlisib was used in combina- Then Hubalek shows data with a protease-activatable tion with fulvestrant after failure of everolimus in the radiometric fluorescent peptide dye conjugate (AVB- BELLE-3 trial. The BROCADE phase II trial added the 620) to identify malignant tissue intraoperatively and PARP inhibitor veliparib to http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Post San Antonio Breast Cancer Symposium

Loading next page...
 
/lp/springer-journals/post-san-antonio-breast-cancer-symposium-ehe2iBvc2K
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-017-0334-4
Publisher site
See Article on Publisher Site

Abstract

editorial memo (2017) 10:50–51 DOI 10.1007/s12254-017-0334-4 Florian Fitzal Received: 9 May 2017 / Accepted: 9 May 2017 / Published online: 30 May 2017 © Springer-Verlag Wien 2017 The 2016 SABCS (San Antonio Breast Cancer Sympo- be a good surrogate marker to differentiate genomic sium) provided delegates with a number of interesting low from high risk. and some praxis-changing data. This issue of memo Finally, Greil and Gampenrieder [3] highlighted highlights the most relevant data from the SABCS pre- data regarding palliative systemic treatment. The PrE- sented by leading breast cancer experts from Austria. GOC 0102 trial investigated whether the combination Locoregional issues are addressed by Michael of fulvestrant plus everolimus is as safe and effective Hubalek [1]. He presents data regarding sentinel node as exemestane plus everolimus for patients with hor- biopsy after neoadjuvant therapy from the GANEA mone-receptor positive, HER2-negative disease. The trial in patients with clinical node-negative disease. pan-PI3K inhibitor buparlisib was used in combina- Then Hubalek shows data with a protease-activatable tion with fulvestrant after failure of everolimus in the radiometric fluorescent peptide dye conjugate (AVB- BELLE-3 trial. The BROCADE phase II trial added the 620) to identify malignant tissue intraoperatively and PARP inhibitor veliparib to

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: May 30, 2017

References